Dose-response effect of prebiotic ingestion (β-glucans isolated from Saccharomyces cerevisiae) in diabetic rats with periodontal disease
Abstract Background Periodontal disease is one of the most frequent comorbidities in diabetic patients and can contribute to poor blood glucose control. Objective To evaluate the effects of ingesting different doses of beta-glucans (BG) isolated from Saccharomyces cerevisiae on alveolar bone loss (A...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-10-01
|
| Series: | Diabetology & Metabolic Syndrome |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13098-021-00729-1 |
| _version_ | 1818575822435385344 |
|---|---|
| author | Diana Vilela Azzi Andressa Naira de Jesus Pereira Viviam de Oliveira Silva Renata de Carvalho Foureaux Andressa Ribeiro Veiga Lima Robson Sfaciotti Barducci Adriana Silva Albuquerque Gabriel Lasmar Reis Raphael Ricon de Oliveira Eric Francelino Andrade Márcio Gilberto Zangeronimo Antonio Chalfun-Júnior Luciano José Pereira |
| author_facet | Diana Vilela Azzi Andressa Naira de Jesus Pereira Viviam de Oliveira Silva Renata de Carvalho Foureaux Andressa Ribeiro Veiga Lima Robson Sfaciotti Barducci Adriana Silva Albuquerque Gabriel Lasmar Reis Raphael Ricon de Oliveira Eric Francelino Andrade Márcio Gilberto Zangeronimo Antonio Chalfun-Júnior Luciano José Pereira |
| author_sort | Diana Vilela Azzi |
| collection | DOAJ |
| description | Abstract Background Periodontal disease is one of the most frequent comorbidities in diabetic patients and can contribute to poor blood glucose control. Objective To evaluate the effects of ingesting different doses of beta-glucans (BG) isolated from Saccharomyces cerevisiae on alveolar bone loss (ABL) and inflammatory/metabolic parameters in normal and diabetic rats with ligature-induced periodontal disease (PD). Design Sixty male rats were assigned into two groups: non-diabetic or diabetic (i.p. 70 mg/kg streptozotocin) with PD. Then, groups were subdivided into five subgroups according BG doses: 0 mg/Kg; 10 mg/Kg; 20 mg/Kg; 40 mg/Kg or 80 mg/Kg. Animals received BG for 28 days and ligatures were placed on lower first molars during the last 14 days. Results ABL of diabetic and non-diabetic animals receiving BG 40 mg/kg (1.33 ± 0.03 mm and 0.77 ± 0.07 mm, respectively) and 80 mg/kg (1.26 ± 0.07 mm and 0.78 ± 0.05 mm, respectively) doses was lower (p < 0.05) in comparison to respective controls (1.59 ± 0.11 mm and 0.90 mm ±0.08). COX-2 (Control: 1.66 ± 0.12; 40 mg/kg: 1.13 ± 0.07; 80 mg/kg: 0.92 ± 0.18) and RANKL expressions (Control: 1.74 ± 0.34; 40 mg/kg: 1.03 ± 0.29 ;80 mg/kg: 0.75 ± 0.21), together with the RANKL/OPG ratio (Control: 1.17 ± 0.08; 40 mg/kg: 0.67 ± 0.09; 80 mg/kg: 0.63 ± 0.28) were attenuated above the same dose (p < 0.05). BG did not influence (p > 0.05) metabolic parameters in non-diabetic rats. In diabetic animals, doses above 40 mg/kg reduced IL-1β (Control: 387 ± 66; 40 mg/kg: 309 ± 27; 80 mg/kg: 300 ± 14) and TNF-α (Control: 229 ± 19; 40 mg/kg: 128 ± 53; 80 mg/kg: 71 ± 25), blood glucose levels (Control: 402 ± 49; 40 mg/kg: 334 ± 32; 80 mg/kg: 287 ± 56), total cholesterol (Control: 124 ± 8; 40 mg/kg: 120 ± 10; 80 mg/kg: 108 ± 9), LDL-c + VLDL-c (Control: 106 ± 8; 40 mg/kg: 103 ± 10; 80 mg/kg: 87 ± 10) and triacylglycerols (Control: 508 ± 90; 40 mg/kg: 301 ± 40; 80 mg/kg: 208 ± 61), whereas increased HDL-c (Control: 18 ± 0.5; 40 mg/kg: 19 ± 1; 80 mg/kg: 21 ± 1) (p < 0.05). Optimal dose needed to reduce ABL was higher in diabetic animals with PD. Conclusions BG ingestion reduced ABL and improved inflammatory profile in a dose-dependent manner. Best effects were achieved with doses above 40 mg/kg. |
| first_indexed | 2024-12-15T00:46:10Z |
| format | Article |
| id | doaj.art-c7b444de66b94206ae63e65f5573ef7f |
| institution | Directory Open Access Journal |
| issn | 1758-5996 |
| language | English |
| last_indexed | 2024-12-15T00:46:10Z |
| publishDate | 2021-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Diabetology & Metabolic Syndrome |
| spelling | doaj.art-c7b444de66b94206ae63e65f5573ef7f2022-12-21T22:41:33ZengBMCDiabetology & Metabolic Syndrome1758-59962021-10-0113111110.1186/s13098-021-00729-1Dose-response effect of prebiotic ingestion (β-glucans isolated from Saccharomyces cerevisiae) in diabetic rats with periodontal diseaseDiana Vilela Azzi0Andressa Naira de Jesus Pereira1Viviam de Oliveira Silva2Renata de Carvalho Foureaux3Andressa Ribeiro Veiga Lima4Robson Sfaciotti Barducci5Adriana Silva Albuquerque6Gabriel Lasmar Reis7Raphael Ricon de Oliveira8Eric Francelino Andrade9Márcio Gilberto Zangeronimo10Antonio Chalfun-Júnior11Luciano José Pereira12Department of Veterinary Medicine, Universidade Federal de Lavras (UFLA)Department of Veterinary Medicine, Universidade Federal de Lavras (UFLA)Department of Veterinary Medicine, Universidade Federal de Lavras (UFLA)Department of Veterinary Medicine, Universidade Federal de Lavras (UFLA)Department of Health Sciences, Universidade Federal de Lavras (UFLA)Department of Research and Development, Biorigin CompanyDepartment of Veterinary Medicine, Universidade Federal de Lavras (UFLA)Department of Biology, Universidade Federal de Lavras (UFLA)Department of Biology, Universidade Federal de Lavras (UFLA)Institute of Agrarian Sciences, Universidade Federal dos Vales do Jequitinhonha e Mucuri (UFVJM)Department of Veterinary Medicine, Universidade Federal de Lavras (UFLA)Department of Biology, Universidade Federal de Lavras (UFLA)Department of Veterinary Medicine, Universidade Federal de Lavras (UFLA)Abstract Background Periodontal disease is one of the most frequent comorbidities in diabetic patients and can contribute to poor blood glucose control. Objective To evaluate the effects of ingesting different doses of beta-glucans (BG) isolated from Saccharomyces cerevisiae on alveolar bone loss (ABL) and inflammatory/metabolic parameters in normal and diabetic rats with ligature-induced periodontal disease (PD). Design Sixty male rats were assigned into two groups: non-diabetic or diabetic (i.p. 70 mg/kg streptozotocin) with PD. Then, groups were subdivided into five subgroups according BG doses: 0 mg/Kg; 10 mg/Kg; 20 mg/Kg; 40 mg/Kg or 80 mg/Kg. Animals received BG for 28 days and ligatures were placed on lower first molars during the last 14 days. Results ABL of diabetic and non-diabetic animals receiving BG 40 mg/kg (1.33 ± 0.03 mm and 0.77 ± 0.07 mm, respectively) and 80 mg/kg (1.26 ± 0.07 mm and 0.78 ± 0.05 mm, respectively) doses was lower (p < 0.05) in comparison to respective controls (1.59 ± 0.11 mm and 0.90 mm ±0.08). COX-2 (Control: 1.66 ± 0.12; 40 mg/kg: 1.13 ± 0.07; 80 mg/kg: 0.92 ± 0.18) and RANKL expressions (Control: 1.74 ± 0.34; 40 mg/kg: 1.03 ± 0.29 ;80 mg/kg: 0.75 ± 0.21), together with the RANKL/OPG ratio (Control: 1.17 ± 0.08; 40 mg/kg: 0.67 ± 0.09; 80 mg/kg: 0.63 ± 0.28) were attenuated above the same dose (p < 0.05). BG did not influence (p > 0.05) metabolic parameters in non-diabetic rats. In diabetic animals, doses above 40 mg/kg reduced IL-1β (Control: 387 ± 66; 40 mg/kg: 309 ± 27; 80 mg/kg: 300 ± 14) and TNF-α (Control: 229 ± 19; 40 mg/kg: 128 ± 53; 80 mg/kg: 71 ± 25), blood glucose levels (Control: 402 ± 49; 40 mg/kg: 334 ± 32; 80 mg/kg: 287 ± 56), total cholesterol (Control: 124 ± 8; 40 mg/kg: 120 ± 10; 80 mg/kg: 108 ± 9), LDL-c + VLDL-c (Control: 106 ± 8; 40 mg/kg: 103 ± 10; 80 mg/kg: 87 ± 10) and triacylglycerols (Control: 508 ± 90; 40 mg/kg: 301 ± 40; 80 mg/kg: 208 ± 61), whereas increased HDL-c (Control: 18 ± 0.5; 40 mg/kg: 19 ± 1; 80 mg/kg: 21 ± 1) (p < 0.05). Optimal dose needed to reduce ABL was higher in diabetic animals with PD. Conclusions BG ingestion reduced ABL and improved inflammatory profile in a dose-dependent manner. Best effects were achieved with doses above 40 mg/kg.https://doi.org/10.1186/s13098-021-00729-1PeriodontitisDiabetes mellitusBone lossInflammatory statusβ-glucans |
| spellingShingle | Diana Vilela Azzi Andressa Naira de Jesus Pereira Viviam de Oliveira Silva Renata de Carvalho Foureaux Andressa Ribeiro Veiga Lima Robson Sfaciotti Barducci Adriana Silva Albuquerque Gabriel Lasmar Reis Raphael Ricon de Oliveira Eric Francelino Andrade Márcio Gilberto Zangeronimo Antonio Chalfun-Júnior Luciano José Pereira Dose-response effect of prebiotic ingestion (β-glucans isolated from Saccharomyces cerevisiae) in diabetic rats with periodontal disease Diabetology & Metabolic Syndrome Periodontitis Diabetes mellitus Bone loss Inflammatory status β-glucans |
| title | Dose-response effect of prebiotic ingestion (β-glucans isolated from Saccharomyces cerevisiae) in diabetic rats with periodontal disease |
| title_full | Dose-response effect of prebiotic ingestion (β-glucans isolated from Saccharomyces cerevisiae) in diabetic rats with periodontal disease |
| title_fullStr | Dose-response effect of prebiotic ingestion (β-glucans isolated from Saccharomyces cerevisiae) in diabetic rats with periodontal disease |
| title_full_unstemmed | Dose-response effect of prebiotic ingestion (β-glucans isolated from Saccharomyces cerevisiae) in diabetic rats with periodontal disease |
| title_short | Dose-response effect of prebiotic ingestion (β-glucans isolated from Saccharomyces cerevisiae) in diabetic rats with periodontal disease |
| title_sort | dose response effect of prebiotic ingestion β glucans isolated from saccharomyces cerevisiae in diabetic rats with periodontal disease |
| topic | Periodontitis Diabetes mellitus Bone loss Inflammatory status β-glucans |
| url | https://doi.org/10.1186/s13098-021-00729-1 |
| work_keys_str_mv | AT dianavilelaazzi doseresponseeffectofprebioticingestionbglucansisolatedfromsaccharomycescerevisiaeindiabeticratswithperiodontaldisease AT andressanairadejesuspereira doseresponseeffectofprebioticingestionbglucansisolatedfromsaccharomycescerevisiaeindiabeticratswithperiodontaldisease AT viviamdeoliveirasilva doseresponseeffectofprebioticingestionbglucansisolatedfromsaccharomycescerevisiaeindiabeticratswithperiodontaldisease AT renatadecarvalhofoureaux doseresponseeffectofprebioticingestionbglucansisolatedfromsaccharomycescerevisiaeindiabeticratswithperiodontaldisease AT andressaribeiroveigalima doseresponseeffectofprebioticingestionbglucansisolatedfromsaccharomycescerevisiaeindiabeticratswithperiodontaldisease AT robsonsfaciottibarducci doseresponseeffectofprebioticingestionbglucansisolatedfromsaccharomycescerevisiaeindiabeticratswithperiodontaldisease AT adrianasilvaalbuquerque doseresponseeffectofprebioticingestionbglucansisolatedfromsaccharomycescerevisiaeindiabeticratswithperiodontaldisease AT gabriellasmarreis doseresponseeffectofprebioticingestionbglucansisolatedfromsaccharomycescerevisiaeindiabeticratswithperiodontaldisease AT raphaelricondeoliveira doseresponseeffectofprebioticingestionbglucansisolatedfromsaccharomycescerevisiaeindiabeticratswithperiodontaldisease AT ericfrancelinoandrade doseresponseeffectofprebioticingestionbglucansisolatedfromsaccharomycescerevisiaeindiabeticratswithperiodontaldisease AT marciogilbertozangeronimo doseresponseeffectofprebioticingestionbglucansisolatedfromsaccharomycescerevisiaeindiabeticratswithperiodontaldisease AT antoniochalfunjunior doseresponseeffectofprebioticingestionbglucansisolatedfromsaccharomycescerevisiaeindiabeticratswithperiodontaldisease AT lucianojosepereira doseresponseeffectofprebioticingestionbglucansisolatedfromsaccharomycescerevisiaeindiabeticratswithperiodontaldisease |